Melanin‐related Metabolites as Markers of Melanoma: A Review

S. Ito

DOI: https://doi.org/10.1111/j.1346-8138.1992.tb03785.x

1992-11-01

Abstract:The incidence of malignant melanoma is increasing worldwide at an alarming rate; it has become a serious social problem in Australia, New Zealand, and sunny areas of the U.SA. (1). The diagnosis and treatment at an early, curable stage are critical for patients with this disease. Furthermore, early detection of metastatic melanoma would be effective in improving the prognosis. Thus, melanoma markers that sensitively detect metastasis have long been awaited. Two types of melanin pigments, the black eumelanin and the reddish-brown pheomelanin, are produced not only in melanocytes but also in melanoma cells (2). They are formed from 5,6dihydroxyindoles or cysteinyldopas (CD) through the tyrosinase oxidation of tyrosine in the absence or presence of cysteine, respectively (Fig. 1). Major portions of these melanin precursors may be oxidized to yield melanin pigments. However, minor portions may be leaked into the blood stream, partly a-methylated in the liver, and excreted in the urine. Thus, it should be possible to estimate the progression of melanoma by measuring the concentrations ofthese melanin-related metabolites in the blood or urine (3). In fact, the urinary excretion of the major isomer ofcysteinyldopas, 5-S-CD, has been used as a biochemical marker of melanoma in some countries, especially in Sweden (4). In addition, a clinical significance for the indolic metabolites such as 5(6)hydroxy-6(5)-methoxyindole-2-carboxylic acid